Complete response, as determined by prostate-specific antigen level, to chlormadinone acetate withdrawal persisting longer than 2 years in patients with advanced prostate cancer: two case reports.

Abstract

Antiandrogen withdrawal syndrome (AWS) is a well-established phenomenon in prostate cancer. However, responses to AWS are usually of limited duration, and a complete response (CR) is extremely rare. We present two patients who exhibited a chemical CR for more than 2 years after the discontinuation of steroidal antiandrogen chlormadinone acetate use. Whether patients who respond to antiandrogen withdrawal include a group of patients with a better prognosis remains uncertain. However, considering that the usual survival period of patients with hormone-resistant prostate cancer is approximately 12 months, both of the patients reported here, who are present in excellent physical condition, exhibiting an improved quality of life, and attending their hospital as outpatients, obviously acquired a prolonged survival because of AWS.

• Authors: Kazumi Noguchi, Jun-Ichi Teranishi, Hiroji Uemura, Naoya Fujikawa, Kazuo Saito, Tetsuo Murai
• Journal: International journal of urology : official journal of the Japanese Urological Association (Int J Urol) Vol. 13 Issue 9 Pg. 1259-61 (Sep 2006) ISSN: 0919-8172 [Print] Australia
• PMID: 16984567 (Publication Type: Case Reports, Journal Article)

Chemical References

• Androgen Antagonists
• Chlormadinone Acetate
• Prostate-Specific Antigen

Topics

• Aged
• Androgen Antagonists (therapeutic use)
• Chlormadinone Acetate (therapeutic use)
• Humans
• Male
• Neoplasms, Hormone-Dependent (drug therapy)
• Prostate-Specific Antigen (blood)
• Prostatic Neoplasms (drug therapy)
• Substance Withdrawal Syndrome
• Survival Rate